Astigmatina Allergy: The Mite Cohort Behind Nearly All IgE-Mediated Mite Disease

Astigmatina is the taxonomic cohort within mite order Sarcoptiformes that contains virtually all IgE-mediated mite allergen sources: house dust mites (Pyroglyphidae), storage mites (Acaridae, Glycyphagidae), tropical dust mites (Echymyopodidae — Blomia tropicalis), and scabies mites (Sarcoptidae). The reason taxonomy matters clinically is that cross-reactivity between Astigmatina families is limited — HDM immunotherapy using Der p 1 and Der p 2 allergens does NOT reliably treat Lepidoglyphus destructor (hay mite) or Tyrophagus putrescentiae (cheese mite) sensitization. Component-resolved diagnostics help identify which specific family is responsible, enabling precise immunotherapy selection.

No. A positive skin prick test to D. pteronyssinus or D. farinae extract confirms Pyroglyphidae sensitization but does not indicate sensitization to storage mite families (Acaridae, Glycyphagidae) or Blomia tropicalis (Echymyopodidae). These families share the NPC2 structural scaffold of group 2 allergens but share only ~40% amino acid identity — insufficient for reliable cross-reactive IgE. Research shows that 56% of storage mite-sensitized patients are NOT co-sensitized to house dust mites. If occupational symptoms (baker, farmer, ham worker) suggest storage mite exposure, specific testing for Lep d 2 and Tyr p 2 is needed alongside standard HDM testing.

House dust mite (Pyroglyphidae) allergy involves sensitization to Der p 1, Der p 2, and Der p 23 from Dermatophagoides species living in mattresses, carpets, and upholstery. Symptoms are perennial and domestic — worst in the bedroom. Storage mite (Acaridae and Glycyphagidae) allergy involves sensitization to Acarus siro, Tyrophagus putrescentiae, Lepidoglyphus destructor, or Glycyphagus domesticus proteins from mites in stored food products, flour, grain, and house dust. Storage mite allergy is more common in occupational settings (bakers, farmers) and may not respond to standard HDM immunotherapy. The key distinguishing test is component-resolved diagnostics: Der p 2 positive with Lep d 2 negative indicates pure HDM allergy; Lep d 2 positive with Der p 2 negative indicates storage mite-only sensitization.

Yes. Oral mite anaphylaxis (also called pancake syndrome) occurs when Astigmatina-sensitized individuals ingest mite-contaminated flour or other grain products. Dermatophagoides, Blomia tropicalis, Tyrophagus putrescentiae, and Acarus siro are all implicated. Mite allergen proteins are thermoresistant — cooking does not destroy them. Symptoms develop 10–240 minutes after ingestion and include urticaria, angioedema, bronchospasm, vomiting, and hypotension. This is most common in tropical and subtropical regions where high humidity allows rapid mite proliferation in stored flour. Prevention centers on refrigerating flour and using it promptly after opening. Epinephrine is the first-line emergency treatment for oral mite anaphylaxis.

Not reliably. Blomia tropicalis (Echymyopodidae) is the dominant indoor mite allergen in tropical and subtropical zones — Singapore, Malaysia, Taiwan, Brazil — with sensitization rates of 73–91% among HDM-allergic patients in those regions. However, its major allergens Blo t 5 and Blo t 21 share low IgE cross-reactivity with Dermatophagoides allergens, and B. tropicalis is not included in most standard European or North American allergy panels. Patients from tropical regions living in temperate climates — or patients traveling frequently to tropical zones — should ask their allergist specifically about Blomia testing if standard HDM testing does not explain their symptom pattern. ODACTRA does not provide meaningful Blomia coverage.

Astigmatina mites cause asthma through the combined action of three major allergen proteins that act on different immune system targets simultaneously. Der p 1 (a cysteine protease) breaches airway epithelial tight junctions, allowing allergens to reach subepithelial immune cells; it also removes CD23 (the IgE downregulator) from B cells, causing IgE overproduction, and removes CD25 from T cells, suppressing regulatory immunity and biasing toward Th2. Der p 2 mimics the TLR4 co-receptor MD-2, acting as an innate immune self-adjuvant that activates NF-κB signaling even at low allergen doses. Der p 23, in fecal pellets, triggers IgE in 74% of HDM-allergic patients and specifically predicts childhood asthma onset. Together, these mechanisms make HDM allergy uniquely efficient at establishing and sustaining airway inflammation.

NPC2 (Niemann-Pick type C2) proteins are lipid-transfer proteins found as group 2 allergens in all major Astigmatina families: Der p 2 (HDM), Lep d 2 (hay mite), Tyr p 2 (cheese mite), Gly d 2 (furniture mite), and Blo t 2 (Blomia). They share a conserved three-dimensional scaffold but only ~40% amino acid identity between Pyroglyphidae and storage mite families. This means they are recognized as IgE allergens by patients sensitized to their respective families, but cross-reactive IgE between families is limited. The NPC2 family also has structural homology to MD-2, which is part of why Der p 2 can substitute for MD-2 in TLR4 signaling — a key mechanism explaining HDM allergy's unusual potency.

Carpet removal is beneficial for HDM allergy but the evidence for clinical benefit is nuanced. Carpet harbors dramatically higher mite populations than hard flooring — hard floors can reduce bedroom allergen levels by 60–80%. However, the 2024 WAO meta-analysis of 35 trials found that multicomponent bedroom interventions (encasings + HEPA + humidity control + carpet removal) achieved statistically significant patient-reported benefit, while single interventions including carpet removal alone did not. If budget allows one renovation, carpet removal in the bedroom where you spend 8 hours nightly is the highest-impact single flooring change. Living areas with less sleeping time are secondary priorities.

Yes. Without immunotherapy, children sensitized to HDM allergens frequently develop new sensitizations over time — to additional indoor allergens, outdoor pollens, and sometimes food allergens. This process is called 'sensitization expansion' and is the molecular basis of the atopic march. Allergen immunotherapy interrupts this process: clinical studies show that AIT reduces new sensitization acquisition (OR 0.49 for monosensitized children versus polysensitized) and prevents asthma development in rhinitic children (PAT study: OR 2.68 for asthma protection at 10-year follow-up). Early intervention in sensitized children is therefore not just symptomatic management — it genuinely alters the long-term disease trajectory.

ODACTRA is an FDA-approved standardized sublingual tablet containing fixed amounts of D. farinae and D. pteronyssinus allergens — Pyroglyphidae family only. It has the strongest regulatory evidence base for HDM rhinitis and asthma in ages 5–65. Custom SLIT drops are off-label formulations that can include any combination of FDA-licensed allergen extracts, including storage mites (Lep d 2, Tyr p 2), Blomia tropicalis, and other Astigmatina allergens not in ODACTRA. Custom drops are critical for patients with polysensitization across Astigmatina families, as ODACTRA alone leaves storage mite or Blomia sensitization unaddressed. The tradeoff is that custom drops have more variable potency and less product-level regulatory standardization than ODACTRA.